Obviously it is too early to sort out the various JAK subtypes at this point in time based on human experience. That is why I said 'kinda like the GABAergics', and that I eagerly await the Ph3's on these compounds. We need to see the Ph3s in RA to understand both the efficacy and malignancy sides of the equation for the current clinical compounds.
OT: Do you see CLF as a good and solid buy at this price point. I just picked some up, FWIW. You can reply on your other board if you care to comment.
Market Data 
Markets 
AI
